Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Pyme francesa ofrece ensayos in vivo para descubrimiento de fármacos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20161124001
Publicado:
16/12/2016
Caducidad:
16/12/2017
Resumen:
Una pyme francesa ha desarrollado una tecnología innovadora de descubrimiento de fármacos y ofrece ensayos in vivo mejorados y rápidos (1 mes en vez de 2-3 meses). La tecnología supone una revolución en el análisis de toxicidad y eficacia de medicamentos contra el cáncer y se basa en analizar moléculas en células cancerígenas humanas injertadas en embriones de pollo. Su coste es entre 5 y 10 veces menor que otras soluciones. La empresa busca laboratorios biotecnológicos y farmacéuticos especializados en cancerología con el fin de establecer acuerdos de servicio y comercialización con asistencia técnica.

Details

Tittle:
A French SME offers in vivo assays for drug discovery
Summary:
A French SME has developed a disruptive technology for drug discovery and proposes improved and accelerated in vivo assays. This technology revolutionizes toxicity and efficacy evaluation of anti-cancer drugs through the testing of drug molecules on human cancer cells grafted onto chick embryos. The partners sought are biotechnology or pharmaceutical laboratories in cancerology. The type of partnership considered is a commercial agreement with technical assistance or a services agreement.
Description:
A French SME offers improved and accelerated In Vivo assays for drug discovery thanks to their disruptive technology. The SME proposes an innovative test to evaluate the toxicity and efficacy of potential anti-cancer new drugs through the testing of drug molecules on human cancer cells grafted onto chick embryos

Indeed, despite the fact that cancer is today the main research topic in developed countries, it remains difficult to efficiently test all interesting molecule candidates. Big pharmaceutical companies see their R-Y-D costs explode and strive to find new cancer drugs. Academics have difficulties to carry out their research due to cost and time issues. Small Biotechs always need to present quicker preclinical results to their investors.
The clinical phases represent two-thirds of the time and development costs; it is therefore essential to remove as soon as possible poorly performing molecules that would fail to pass these steps.

The technology offered by the SME is a new screening tool for the selection of drug molecules from a set of potential candidates. The SME proposes time and cost-effective drug validation for growing human tumors on the chicken egg model before any animal testing. The SME in vivo tests precede the existing mouse model and allow testing of many more valuable candidates than current methods. Thus, it greatly improves the least efficient step in drug development: the lead validation or lead optimisation.

The partners sought are biotechnology or pharmaceutical laboratories in cancerology.

The French SME will commission a commercial agreement with technical assistance or services agreement to evaluate the molecules or candidate compunds delivered by the partner. Dependent on the results the French SME and the partner will work together to develop a proof of concept.
Advantages and Innovations:
o Faster results: 1 month instead of 2-3
o Higher sensitivity: 1000 times less compound needed
o Stronger reliability: high statistical significance
o In vivo assays, but with no animal testing
o Affordable: costs 5-10 times less than comparable
o Early stage evaluation to eliminate low value molecules, before mouse studies
o Great predictivity, using the same cancer cell lines as other predictive models
Stage of Development:
Already on the market
IPs:
Patents granted,Exclusive Rights
CommeR Statunts Regarding IPR Status:
IPR is based on 5 years of public research

Partner sought

Type and Role of Partner Sought:
Type of partner sought:
Small or large biotechnology and/or pharmaceutical laboratories in cancerology looking for fast and affordable means for selecting molecules for mouse testing.

Task to be performed by the partner sought:
The partners or clients may deliver:
Molecules for preclinical in vivo testing, candidate compounds for in vivo toxicological testing.

The French SME will commission a commercial agreement with technical assistance or services agreement to evaluate the molecules or candidate compunds. Dependent on the results the French SME and the partner will work together to develop a proof of concept.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica
06002010 Toxicología